AbbVie wins reversal of $140 million verdict in case over AndroGel risks
(Reuters) - A U.S. judge on Thursday overturned a $140.1 million verdict against AbbVie Inc in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack. (Source: Reuters: Health)
Source: Reuters: Health - July 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
U.S. judge tosses $140 million verdict against AbbVie in AndroGel case
(Reuters) - A U.S. judge on Thursday overturned a $140 million verdict against AbbVie Inc in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack. (Source: Reuters: Health)
Source: Reuters: Health - July 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
AbbVie, AndroGel partner owe $448 million in antitrust case: U.S. judge
(Reuters) - A U.S. judge on Friday found that pharmaceutical company AbbVie Inc used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million. (Source: Reuters: Health)
Source: Reuters: Health - June 30, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Abbvie, Androgel partner owe $488 million in antitrust case: U.S. judge
(Reuters) - A U.S. judge on Friday found that Abbvie Inc used sham litigation to illegally prevent generic versions of testosterone gel AndroGel from getting to market and ordered the drugmaker and its partner to pay $488 million. (Source: Reuters: Health)
Source: Reuters: Health - June 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
U.S. Jury Orders AbbVie to Pay $3 Mln in AndroGel Retrial U.S. Jury Orders AbbVie to Pay $3 Mln in AndroGel Retrial
A U.S. jury ordered AbbVie to pay more than $3 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, though the jury did not find AbbVie strictly liable.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 27, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
U.S. jury orders AbbVie to pay $3 million in AndroGel retrial
NEW YORK (Reuters) - A U.S. jury on Monday ordered AbbVie Inc to pay more than $3 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, though the jury did not find AbbVie strictly liable. (Source: Reuters: Health)
Source: Reuters: Health - March 26, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
AbbVie Wins U.S. Trial in Lawsuit Over AndroGel's Risks AbbVie Wins U.S. Trial in Lawsuit Over AndroGel's Risks
A federal jury in Chicago on Friday found AbbVie Inc not liable in a lawsuit by an Arizona man who claimed he had suffered a pulmonary embolism due to using the company ' s testosterone replacement medication AndroGel.Reuters Health Information (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 31, 2018 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
AbbVie wins U.S. trial in lawsuit over AndroGel's risks
(Reuters) - A federal jury in Chicago on Friday found AbbVie Inc not liable in a lawsuit by an Arizona man who claimed he had suffered a pulmonary embolism due to using the company's testosterone replacement medication AndroGel. (Source: Reuters: Health)
Source: Reuters: Health - January 27, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
U.S. judge tosses verdict against AbbVie in AndroGel case
(Reuters) - A U.S. judge on Friday overturned a $150 million verdict against AbbVie Inc that was first to result from lawsuits claiming that the company fraudulently misrepresented the risks of its testosterone replacement drug AndroGel. (Source: Reuters: Health)
Source: Reuters: Health - December 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
U.S. judge tosses $150 million verdict against AbbVie in AndroGel case
(Reuters) - A U.S. judge on Friday overturned a $150 million verdict against AbbVie Inc in the first federal court case to go to trial over claims that the company fraudulently misrepresented the risks of its testosterone replacement drug AndroGel. (Source: Reuters: Health)
Source: Reuters: Health - December 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Testosterone Gel Packets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - November 6, 2017 Category: Drugs & Pharmacology Source Type: news
Second U.S. jury finds AbbVie misrepresented risks of AndroGel
(Reuters) - A U.S. jury on Thursday ordered AbbVie Inc to pay more than $140 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, the plaintiff's lawyer said in a statement. (Source: Reuters: Health)
Source: Reuters: Health - October 5, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
AbbVie hit with $140 million verdict in AndroGel trial: lawyer
(Reuters) - A U.S. jury on Thursday ordered AbbVie Inc to pay more than $140 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, the plaintiff's lawyer said in an emailed statement. (Source: Reuters: Health)
Source: Reuters: Health - October 5, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Dose-Response Effects of T Gel in Medically Castrated Men Dose-Response Effects of T Gel in Medically Castrated Men
A new study examines the treatment effects of variable doses of transdermal testosterone gel among medically castrated men.Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 21, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
U.S. Jury Finds AbbVie Liable for Misrepresentation in First AndroGel Verdict U.S. Jury Finds AbbVie Liable for Misrepresentation in First AndroGel Verdict
A federal jury in Chicago on Monday found AbbVie Inc fraudulently misrepresented the risks of its testosterone replacement drug AndroGel and ordered the drugmaker to pay $150 million in punitive damages.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 25, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news
